What's Happening?
Neurelis, Inc., the company behind VALTOCO (diazepam nasal spray), announced its participation in the 13th Annual Sofie's Journey Epilepsy Awareness Day & Education Expo at Disneyland Resort. The event
aims to increase epilepsy education and support for individuals with epilepsy, their families, and healthcare practitioners. Neurelis will engage with the community, sharing experiences and promoting VALTOCO, an FDA-approved treatment for episodes of frequent seizures in patients aged two years and older. The company will sponsor presentations by its ambassadors, who will share their personal journeys and experiences with epilepsy and VALTOCO.
Why It's Important?
Neurelis' involvement in the Epilepsy Awareness Day & Education Expo highlights the company's commitment to supporting the epilepsy community and raising awareness about seizure management. By participating in this event, Neurelis aims to educate attendees about the benefits of VALTOCO and provide support to those affected by epilepsy. The event serves as a platform for the company to connect with patients, caregivers, and healthcare professionals, fostering a sense of community and shared understanding. This engagement may enhance Neurelis' reputation and strengthen its position in the epilepsy treatment market.
What's Next?
Neurelis will continue to advocate for individuals with epilepsy and promote VALTOCO as a reliable treatment option. The company may explore additional opportunities to engage with the epilepsy community through events, partnerships, and educational initiatives. Neurelis' ongoing efforts to support epilepsy awareness and education could lead to increased adoption of VALTOCO and further advancements in seizure management.
Beyond the Headlines
The event underscores the importance of community support and education in managing chronic health conditions like epilepsy. It highlights the role of pharmaceutical companies in not only developing treatments but also actively participating in patient advocacy and education. Neurelis' involvement reflects a broader trend of companies engaging with patient communities to build trust and improve healthcare outcomes.
